AJP - Endo Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Endocrinol Metab 286: E621-E625, 2004. First published December 16, 2003; doi:10.1152/ajpendo.00499.2003
0193-1849/04 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
286/4/E621    most recent
00499.2003v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (24)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Meier, J. J.
Right arrow Articles by Nauck, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Meier, J. J.
Right arrow Articles by Nauck, M. A.

Gastric inhibitory polypeptide does not inhibit gastric emptying in humans

Juris J. Meier,1 Oliver Goetze,1 Jens Anstipp,1 Dirk Hagemann,1 Jens J. Holst,2 Wolfgang E. Schmidt,1 Baptist Gallwitz,1 and Michael A. Nauck3

1Department of Medicine I, St. Josef-Hospital, Ruhr-University Bochum, 44791 Bochum; 3Diabeteszentrum, 37431 Bad Lauterberg, Germany; and 2Department of Medical Physiology, The Panum Institute, University of Copenhagen, 2200 Copenhagen, Denmark

Submitted 5 November 2003 ; accepted in final form 10 December 2003

The insulinotropic gut hormone gastric inhibitory polypeptide (GIP) has been demonstrated to inhibit gastric acid secretion and was proposed to possess "enterogastrone" activity. GIP effects on gastric emptying have not yet been studied. Fifteen healthy male volunteers (23.9 ± 3.3 yr, body mass index 23.7 ± 2.3 kg/m2) were studied with the intravenous infusion of GIP (2 pmol·kg-1·min-1) or placebo, each administered to the volunteers on separate occasions from -30 to 360 min in the fasting state. At 0 min, a solid test meal (250 kcal containing [13C]sodium octanoate) was served. Gastric emptying was calculated from the 13CO2 exhalation rates in breath samples collected over 360 min. Venous blood was drawn in 30-min intervals for the determination of glucose, insulin, C-peptide, and GIP (total and intact). Statistical calculations were made by use of repeated-measures ANOVA and one-way ANOVA. During the infusion, GIP rose to steady-state concentrations of 159 ± 15 pmol/l for total and 34 ± 4 pmol/l for intact GIP (P < 0.0001). Meal ingestion further increased GIP concentrations in both groups, reaching peak levels of 265 ± 20 and 82 ± 9 pmol/l for total and 67 ± 7 and 31 ± 9 pmol/l for intact GIP during the administration of GIP and placebo, respectively (P < 0.0001). There were no differences in glucose, insulin, and C-peptide between the experiments with the infusion of GIP or placebo. Gastric half-emptying times were 120 ± 9 and 120 ± 18 min (P = 1.0, with GIP and placebo, respectively). The time pattern of gastric emptying was similar in the two groups (P = 0.98). Endogenous GIP secretion, as derived from the incremental area under the curve of plasma GIP concentrations in the placebo experiments, did not correlate to gastric half-emptying times (r2 = 0.15, P = 0.15 for intact GIP; r2 = 0.21, P = 0.086 for total GIP). We conclude that gastric emptying does not appear to be influenced by GIP. The secretion of GIP after meal ingestion is not suppressed by its exogenous administration. The lack of effect of GIP on gastric emptying underlines the differences between GIP and the second incretin glucagon-like peptide 1.

glucose-dependent insulinotropic polypeptide; enterogastrone; incretin hormones


Address for reprint requests and other correspondence: J. J. Meier, Division of Endocrinology and Diabetes, Keck School of Medicine, Univ. of Southern California, 1333 San Pablo St., BMT-BII, Los Angeles, CA 90033 (E-Mail: jmeier{at}usc.edu).




This article has been cited by other articles:


Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
A. N. Pilichiewicz, R. Chaikomin, I. M. Brennan, J. M. Wishart, C. K. Rayner, K. L. Jones, A. J. P. M. Smout, M. Horowitz, and C. Feinle-Bisset
Load-dependent effects of duodenal glucose on glycemia, gastrointestinal hormones, antropyloroduodenal motility, and energy intake in healthy men
Am J Physiol Endocrinol Metab, September 1, 2007; 293(3): E743 - E753.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
J Schirra, M Nicolaus, R Roggel, M Katschinski, M Storr, H J Woerle, and B Goke
Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans
Gut, February 1, 2006; 55(2): 243 - 251.
[Abstract] [Full Text] [PDF]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
B. D Green, N. Irwin, V. A Gault, F. P. O'Harte, and P. R Flatt
Review: Development and therapeutic potential of incretin hormone analogues for type 2 diabetes
The British Journal of Diabetes & Vascular Disease, May 1, 2005; 5(3): 134 - 140.
[Abstract] [PDF]

Home page
 DiabetesHome page
T. Miki, K. Minami, H. Shinozaki, K. Matsumura, A. Saraya, H. Ikeda, Y. Yamada, J. J. Holst, and S. Seino
Distinct Effects of Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 on Insulin Secretion and Gut Motility
Diabetes, April 1, 2005; 54(4): 1056 - 1063.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2004 by the American Physiological Society.